生物醫藥技術全國重點實驗室
（香港大學）
State Key Laboratory of Pharmaceutical Biotechnology
（The University of Hong Kong)
Field of Research
Development of multiple types of immunoassays, followed by validation across diverse patient cohorts to ensure diagnostic accuracy and clinical utility.
Biography
Dr. Ku Kam Ching is currently a post-doctoral fellow in ImmunoDiagnostics Limited (IMD), a spin-off biotech company from the University of Hong Kong. He received his BSc in Molecular Biology & Biotechnology at the University of Hong Kong in 2016, MSc in Biotechnology at The Hong Kong University of Science and Technology in 2017, and PhD in Clinical Medicine at the University of Hong Kong in 2024.
Publications
-
Ku KC, Zhong J, Song E, Fong CH, Lam KS, Xu A, Lee CH, Cheung CY. Clinical utility of glycated albumin and 1,5-anhydroglucitol in the screening and prediction of diabetes: A multi-center study. World J Diabetes. 2025 Apr 15;16(4):102867.
-
Qiu H, Song E, Hu Y, Li T, Ku KC, Wang C, Cheung BMY, Cheong LY, Wang Q, Wu X, Hoo RLC, Wang Y, Xu A. Hepatocyte-Secreted Autotaxin Exacerbates Nonalcoholic Fatty Liver Disease Through Autocrine Inhibition of the PPARα/FGF21 Axis. Cell Mol Gastroenterol Hepatol. 2022;14(5):1003-1023.